• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
    • Promotional Marketing Toolkit
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment

April 26, 2021

– Findings Published as Congress Demands Review of Medicare Coverage for Non-opioid Treatments –

Cleveland, Ohio- April 26, 2021- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists,demonstrated significant reductions in postoperative opioid use and pain following percutaneous peripheral nerve stimulation (PNS) compared to placebo. Participants undergoing painful orthopedic surgical procedures such as rotator cuff repair were randomized to receive PNS or placebo stimulation as part of the study.  Based on the results of the study, lead investigator, Dr. Brian Ilfeld, and co-authors concluded that “percutaneous peripheral nerve stimulation is highly effective for acute pain.”

  • Patients treated with PNS consumed 80 percent less opioids in the first seven postoperative days compared to those in the placebo control group (P<0.001).
  • Even when taking fewer opioids, patients receiving PNS treatment reported significantly lower pain scores that were one-third of those in the control group (P<0.001).
  • None (0 percent) of the patients treated with PNS were using opioids at one month following surgery, while 18 percent of the placebo patients continued taking opioids.

David Dickerson, MD, Chairman, Committee on Pain Medicine, American Society of Anesthesiologists, and section chief for pain medicine, NorthShore University Health System said, “It is clear that surgery and postoperative opioid prescriptions can be a gateway to persistent opioid use and potential opioid use disorder. Furthermore, surpluses of post-surgical opioid prescriptions can be a source of misuse or abuse by individuals for whom the medicines were not prescribed. This study highlights a meaningful role for PNS in the non-opioid management of acute surgical pain. As reflected in the study’s findings, PNS provides a high impact, opioid-sparing, postoperative pain treatment and comes at an important time as Congress is working to identify Medicare payment and coverage policies that promote or unnecessarily leverage opioids over safe and effective non-opioid treatments. Perioperative PNS treatment provides exactly the kind of evidence-based, FDA-cleared technology for which the NOPAIN Act was drafted.  Support for coverage of PNS for acute pain as part of the Congressional initiatives presently underway would be an important step forward in promoting access to a safe and effective non-opioid pain management treatment.”

About the SPRINT® PNS System

The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough, restorative, 60-day treatment is a First-Line™ PNS option uniquely designed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and is cleared for use up to 60 days. Recognized by leading pain management centers, the breakthrough neuromodulation treatment offers a patient-preferred alternative to more invasive options.

For additional information regarding safety and efficacy visit www.SprintPNS.com.

About SPR Therapeutics, Inc.
SPR Therapeutics is a privately-held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain.

More information can be found at www.SPRTherapeutics.com.

# # #

SPR Contact:
Mark Stultz
Senior Vice President
mstultz@sprtherapeutics.com

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: NewsTag: 60-day percutaneous PNS, clinical study, PNS
Previous Post:Collaborative Chronic Pain Management between Pain Specialists and Physical Therapists
Next Post:Peripheral Nerve Stimulation is a Promising Non-Opioid Alternative for Acute and Subacute Post-Amputation Pain Treatment

Reader Interactions

Comments

  1. Jan Johnson

    September 27, 2021 at 11:38 pm

    I just saw Dr. Dickerson discussing Sprint PNS for nerve pain. My husband suffers from Hemicrania maxima and his quality of life is compromised significantly during bouts of this severe pain. Would / Has a Sprint PNS ever been used to treat Hemicrania?

    Reply
    • SPR Therapeutics

      September 30, 2021 at 1:58 pm

      We are sorry, but the SPRINT PNS System is not intended to treat pain in the craniofacial region.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sidebar

Archives

Recent News

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Sprint Regional Lab Fluoro Only – Boston

Sprint Regional Lab – Boston

SPRINT PNS Regional Lab & APP Program: Kansas City

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo